Zomedica enters assay development agreement with IncellDx
IncellDx announced it has entered into an assay development agreement with Zomedica to identify and enumerate circulating tumor cells, or CTCs, from canine cancers using its BioINK liquid biopsy reagent platform. The investigational assay will incorporate biomarkers from Zomedica's canine cancer research programs with IncellDx's core BioINK reagents and novel cell cycle capabilities on CTCs. The Celsee Genesis system was designed to provide way for scientists to analyze and interpret cellular behavior and collect critical cell-based information that was previously undetectable. Zomedica entered into a license and supply agreement with Celsee in 2017 to develop and market the Genesis liquid biopsy platform for use by veterinarians as a cancer diagnostic. Celsee also previously partnered with IncellDx on a lung cancer/CTC PD-L1 feasibility study leading to a co-commercialization agreement.